Table 5.
Studies analyzing clinical impact of MALDI-TOF with prospective design or using a comparator.
| Reference | Year | Design | Result | Comment |
|---|---|---|---|---|
| Vlek [100] | February-April 2010 | Prospective comparative study. | - Reduction of species identification time by 28.8 hours. - Increase of 11.3% in the proportion of patients with appropriate treatment. |
- Does not evaluate mortality or cost-effectiveness |
| Huang [101] | September- November 2012 | Pre-post quasi-experimental study. | - Integration of MALDI-TOF with AMS team reduces microorganism identification time and time to effective treatment. - Mortality, length of stay and recurrent bacteremia were lower in the intervention group. |
- Integration with AMS team. |
| Clerc [102] | 2010 | Prospective, observational | - MALDI-TOF had an impact on 35% of Gram-negative bacteremia cases. | - Single arm. - Does not evaluate hospital stay, clinical impact or mortality. |
| Perez. [103] | 2012-2013 | Quasi-experimental study. | - Reduced time to optimal and effective treatment, shorter hospitalization time, lower mortality and estimated lower associated costs. | - Integration with AMS team. |
| Verroken [104] | 2013-2014 | Prospective comparative study with two sequential intervention periods. | - Reduced time to identification and time to optimal treatment | - Integration with AMS team. |
| Lockwood [105] | 2014 | Prospective comparative study. | - Reduced time to identification and time to optimal treatment | - Integration with AMS team. |
| Osthoff [106] | 2014-2015 | Prospective, open-label, controlled clinical trial | - Reduced treatment of contaminated blood cultures - Shorter time to active treatment and admission to ICU in intervention group |
- Integration with AMS team. |
| O’Donnell [107] | 2015 | Pragmatic, controlled clinical trial | - Shorter time to definitive treatment, shorter antibiotic therapy and shorter hospital stay | - Integration with AMS team. |
AMS: antimicrobial stewardship